82 related articles for article (PubMed ID: 23156293)
1. [Molecular genetic of ovarian cancer].
Yanaihara N; Okamoto A; Ochiai K; Tanaka T
Nihon Rinsho; 2012 Jun; 70 Suppl 4():475-9. PubMed ID: 23156293
[No Abstract] [Full Text] [Related]
2. [Genetic abnormalities in the pathogenesis of ovarian cancer].
Yoshino K; Ueda Y; Kimura T; Kobayashi E; Fujita M; Enomoto T
Nihon Rinsho; 2012 Jun; 70 Suppl 4():480-7. PubMed ID: 23156294
[No Abstract] [Full Text] [Related]
3. [Molecular genetics of ovarian cancer].
Yanaihara N; Okamoto A; Takakura S; Yamada K; Ochiai K; Tanaka T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():441-8. PubMed ID: 15535284
[No Abstract] [Full Text] [Related]
4. Ovarian cancer : making its own rules-again.
Kohn EC; Hurteau J
Cancer; 2013 Feb; 119(3):474-6. PubMed ID: 23233093
[TBL] [Abstract][Full Text] [Related]
5. The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan S; Bates V; Lord R; Green JA
Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.
Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697
[TBL] [Abstract][Full Text] [Related]
7. [Recent developments in the molecular genetic understanding of ovarian carcinoma].
Shimizu Y
Nihon Rinsho; 2004 Oct; 62 Suppl 10():489-95. PubMed ID: 15535294
[No Abstract] [Full Text] [Related]
8. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
9. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas.
Niskakoski A; Kaur S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Int J Cancer; 2013 Dec; 133(11):2596-608. PubMed ID: 23716351
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
[TBL] [Abstract][Full Text] [Related]
11. Personalized therapy in gynecological cancer: a reality in clinical practice?
Banerjee S; Gore M
Curr Oncol Rep; 2013 Jun; 15(3):201-3. PubMed ID: 23532395
[No Abstract] [Full Text] [Related]
12. Beyond the KRAS test.
Laurent-Puig P; Lièvre A; Blons H
Eur J Cancer; 2009 Sep; 45 Suppl 1():398-9. PubMed ID: 19775645
[No Abstract] [Full Text] [Related]
13. Mutations in the KRAS gene in ovarian tumors.
Dobrzycka B; Terlikowski SJ; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(2):221-4. PubMed ID: 19995707
[TBL] [Abstract][Full Text] [Related]
14. [Examination of molecular markers used n the treatment of colon cancer].
Domagała P; Kowalik A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
[No Abstract] [Full Text] [Related]
15. [Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].
Ueno T; Moriwaki T; Hyodo I
Nihon Rinsho; 2011 Apr; 69 Suppl 3():477-81. PubMed ID: 22214007
[No Abstract] [Full Text] [Related]
16. High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer.
Zikan M; Janatova M; Pavlista D; Pohlreich P
J Genet; 2007 Aug; 86(2):169-71. PubMed ID: 17968145
[No Abstract] [Full Text] [Related]
17. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
18. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
19. KRAS 3'-UTR variants and stratification of breast-cancer risk.
Kumar MS; Swanton C
Lancet Oncol; 2011 Apr; 12(4):318-9. PubMed ID: 21435949
[No Abstract] [Full Text] [Related]
20. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
[Next] [New Search]
